BRCA1, the gene responsible for approximately half of all cases of hereditary breast cancer and almost all cases of combined hereditary breast and ovarian cancer, has been implicated in the maintenance of genomic stability through DNA repair. This function is mediated, at least in part, through two tandem BRCA1 C-terminal (BRCT) repeats. The role of BRCA1 in the development of ovarian cancer is poorly understood, partially owing to the lack of ovarian cancer cell lines with defective BRCA1. The purpose of this study was to further characterize an endometrioid ovarian cancer cell line, SNU-251, which was previously reported to carry a nonsense mutation (from G to A) at amino acid 1815 of BRCA1. In addition, we examined the role of BRCA1 in the cell cycle and in the responses to the chemotherapy drug paclitaxel and ionizing radiation. Loss of the C-terminal 49 amino acids due to this point mutation did not affect the expression of the truncated BRCA1 protein, but caused a loss of transcriptional activation of the endogenous p21 WAF1/CIP1 gene, and could not sustain arrest in the G 2 /M phase of the cell cycle. The BRCA1 mutation in SNU-251 cells inhibited BRCA1 subnuclear assembly for DNA-damage repair and increased cellular sensitivity to ionizing radiation and paclitaxel. This sensitivity was reversed by reintroduction of ectopic wild-type BRCA1. Our results suggest that the deletion of the C-terminal 49 amino acids of BRCA1 results in a loss of BRCA1 function in the SNU-251 cell line. BRCA1 helps to mediate the resistance to both radiation and paclitaxel. Therefore, SNU-251 may be a useful model for studying the molecular mechanism of BRCA1 in the resistance of ovarian cancer to ionizing radiation and chemotherapy treatment and in the development of hereditary human ovarian cancer.
BRCA1, the gene responsible for approximately half of all cases of hereditary breast cancer and almost all cases of combined hereditary breast and ovarian cancer, has been implicated in the maintenance of genomic stability through DNA repair. This function is mediated, at least in part, through two tandem BRCA1 C-terminal (BRCT) repeats. The role of BRCA1 in the development of ovarian cancer is poorly understood, partially owing to the lack of ovarian cancer cell lines with defective BRCA1. The purpose of this study was to further characterize an endometrioid ovarian cancer cell line, SNU-251, which was previously reported to carry a nonsense mutation (from G to A) at amino acid 1815 of BRCA1. In addition, we examined the role of BRCA1 in the cell cycle and in the responses to the chemotherapy drug paclitaxel and ionizing radiation. Loss of the C-terminal 49 amino acids due to this point mutation did not affect the expression of the truncated BRCA1 protein, but caused a loss of transcriptional activation of the endogenous p21 WAF1/CIP1 gene, and could not sustain arrest in the G 2 /M phase of the cell cycle. The BRCA1 mutation in SNU-251 cells inhibited BRCA1 subnuclear assembly for DNA-damage repair and increased cellular sensitivity to ionizing radiation and paclitaxel. This sensitivity was reversed by reintroduction of ectopic wild-type BRCA1. Our results suggest that the deletion of the C-terminal 49 amino acids of BRCA1 results in a loss of BRCA1 function in the SNU-251 cell line. BRCA1 helps to mediate the resistance to both radiation and paclitaxel. Therefore, SNU-251 may be a useful model for studying the molecular mechanism of BRCA1 in the resistance of ovarian cancer to ionizing radiation and chemotherapy treatment and in the development of hereditary human ovarian cancer. Oncogene (2003 Oncogene ( ) 22, 2396 Oncogene ( -2404 Oncogene ( . doi:10.1038 Keywords: ovarian cancer; BRCA1; cell cycle; ionizing radiation; paclitaxel Germline mutations in BRCA1 are responsible for approximately half of all cases of hereditary breast cancer and for almost all cases of combined hereditary breast and ovarian cancer (Easton et al., 1993) . BRCA1 encodes a 1863-amino-acid nuclear phosphoprotein that is maximally expressed during the S phase of the cell cycle (Chen et al., 1996; Scully et al., 1996) . Exposure to g-radiation, ultraviolet (UV) light, or the DNA-replication inhibitor hydroxyurea causes rapid phosphorylation of BRCA1, indicating that BRCA1 is a target of the DNA damage response pathway (Scully et al., 1997a) . In the absence of DNA damage, BRCA1 is localized to discrete nuclear foci during the S and G 2 phases of the cell cycle. Exposure to DNA-damaging reagents induces localization of BRCA1 to new loci, some of which are sites of DNA synthesis. BRCA1 interacts with both Rad51, a human homologue of bacterial RecA that is involved in homologous chromosome recombination and DNA repair following exposure of the cell to irradiation (Scully et al., 1997b; Chen et al., 1998 Chen et al., , 1999 and the RAD50-Mre11-p95 complex, which is involved in nonhomologous DNA repair (Zhong et al., 1999) . BRCA1 can arrest the cell cycle by stimulating transcription of the cyclin-dependent kinase inhibitor p21 WAF/CIP1 (Somasundaram et al., 1997 (Somasundaram et al., , 1999 . In addition, BRCA1 binds p53 and works with p53 cooperatively in vivo (Ouchi et al., 1998; Zhang et al., 1998; Chai et al., 1999) . Although complete BRCA1 knockout mice exhibited a lethal phenotype, BRCA1 conditional knockout mice showed the following characteristics in the mammary epithelial cells of female mice: genetic instability, blunted ductal morphogenesis, and breast tumor formation (Xu et al., 1999a,b) .
The C-terminal region of BRCA1 contains two tandem BRCA1 C-terminal (BRCT) repeats that are homologous to many proteins involved in DNA repair (Bork et al., 1997; Callebaut and Mornon, 1997) . A large number of BRCA1 germline mutations have been detected in the BRCT repeats and throughout the entire coding region of BRCA1 in patients with familial breast and ovarian cancer. Although many BRCA1 mutations have been identified in lymphocytes and tumor samples from patients with breast and ovarian cancer, very few breast or ovarian cancer cell lines carrying BRCA1 germline mutations are available to allow detailed experimental analysis of the function of the BRCA1 protein. The breast cancer cell line HCC1937 (Tomlinson et al., 1998) , which carries the BRCA1 5382 insC mutation, has been widely used to analyse the function of BRCA1 (Cortez et al., 1999; Scully et al., 1999; Zhong et al., 1999) . A mutation in this cell line causes truncation of the BRCA1 protein and loss of the entire second BRCT repeat. Only two reports have described an ovarian cancer cell line, SNU-251, which carries a (Yuan et al., 1997) . Wild-type BRCA1 (220 kDa) in SK-OV3 cells and a truncated form of BRCA1 (210 kDa) in SNU-251 cells are indicated by small and large arrows, respectively. Western blot analysis was performed as previously described (Scully et al., 1997a; Liu et al., 2000) . (c) Loss of immunoreactivity of truncated BRCA1 protein to the anti-BRCA1 C-terminal antibody C-20. The membrane from (b) was stripped and reprobed with the anti-BRCA1 (C-20) antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). (d) Western blot analysis of mutant p53 protein expression in SNU-251 and primary cultured normal ovarian surface epithelial (NOE) cells. The method used for detecting p53 was the same as in (b), except anti-p53 antibody (DO1, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was used instead of anti-BRCA1 (ab1) monoclonal antibody. NOE cells were cultured from oophorectomy specimens from patients with benign conditions and cultured in MCDB105/Medium 199 (ratio: 1 : 1) medium containing 15% fetal bovine serum (FBS) and antibiotics, (e) Western blot analysis of the PTEN protein in SNU-251 cells. The method used for detecting PTEN was the same as in (b), except that anti-PTEN antibody was used instead of anti-BRCA1 (ab1) monoclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). b-Actin was used as the internal control in all Western blot analyses. SNU-251, SK-OV3, and HeLa cells purchased from the American Type Culture Collection (ATCC) were cultured in RMPI 1640 medium supplemented with 10% FBS and antibiotics at 371C in a 5% CO 2 incubator Role of BRCA1 in resistance to paclitaxel and ionizing radiation C Zhou et al single-base G-to-A transition in exon 23, resulting in a stop codon at amino acid 1815 of BRCA1 and a predicted loss of half of the second BRCT repeat (Yuan et al., 1997; Park, 2002) . However, limited characterization of SNU-251 prevents its widespread use as a model system for hereditary ovarian cancer because it is unclear whether this cell line has the phenotype attributed to the defective BRCA1 gene. The purpose of this study was to further characterize the SNU-251 cell line, to compare it with a sporadic ovarian cancer cell line SK-OV3 carrying wild-type BRCA1, and to determine the role of BRCA1 in resistance to both ionizing radiation and paclitaxel.
The BRCA1 mutation in the SNU-251 cell line is predicted to cause the loss of the C-terminal 49 amino acids of the BRCA1 protein, which contain the second half of the BRCT repeat. Figure 1a shows a schematic of the major known functional BRCA1 domains. Using DNA sequence analysis, we confirmed a single-base (G-to-A) mutation of BRCA1 in exon 23 in the SNU-251 cell line (data not shown). Western blot analysis showed a 210-kDa BRCA1 protein in the SNU-251 cells and a 220-kDa BRCA1 protein in the SK-OV3 cells ( Figure 1b ).
To further demonstrate that the C-terminal 49 amino acids were lost in the truncated 210-kDa BRCA1 protein, we examined protein expression using the anti-BRCA1 (C-20) antibody, which specifically recognizes the C-terminus of BRCA1. The anti-BRCA1 (C-20) antibody did not recognize the BRCA1 protein in the SNU-251 cells but did recognize the wild-type BRCA1 protein in the SK-OV3 cells (Figure 1c) , demonstrating that the DNA in SNU-251 cells encodes a truncated BRCA1 protein lacking the last 49 amino acids. In addition, we sequenced the p53 gene in the SNU-251 cells and showed a previously described threebase TCA deletion in exon 7 (data not shown). Western blot analysis showed a high expression level of mutant p53 protein in the SNU-251 cells but not in normal ovarian surface epithelial (NOE) cells (Figure 1d ).
Because a high incidence of PTEN gene mutation in endometrioid ovarian cancer has been reported (Risinger et al., 1996; Steck et al., 1997; Sun et al., 2001) , we sequenced all nine exons of the PTEN gene in SNU-251 cells, using 11 pairs of PTEN DNA sequence primers. The sequencing primers and methods were as described previously (Risinger et al., 1996; Steck et al., 1997; Sun et al., 2001) . We found no mutations in any of the nine exons of the PTEN gene in the SNU-251 cells, but we did find a single-base C deletion in intron 3, a singlebase A-to-G substitution in intron 4, and a single-base G-to-T substitution in intron 8 (Table 1) . Western blot analysis also showed that the expression level of the wild-type PTEN protein (50 kDa) in the SNU-251 cells ( Figure 1e ) was similar to that in HeLa cells, which contain wild-type PTEN protein. On the basis of these results, we concluded that there are no mutations in the functional region of the PTEN gene that affect PTEN protein expression in the SNU-251 endometroid ovarian cancer cell line, despite the high frequency of PTEN mutations that has been reported in ovarian endometrioid carcinoma (Sato et al., 2000) .
BRCA1 has been shown to interact with p53 through the C-terminal BRCT repeats of BRCA1 (Monteiro et al., 1996; Ouchi et al., 1998; Chai et al., 1999) . It is unclear whether the deletion of last 49 amino acids of the second BRCT repeat is sufficient to disrupt the function of the BRCA1 protein or whether the two repeats are functionally redundant and serve as a protective mechanism against DNA damage. To determine the function of the last 49 amino acids, we constructed three in vitro expression vectors: pcDNA3 (wtBRCA1), which contains the wild-type BRCA1 gene; pcDNA3 (BRCA1 (D1815-1863)), which is identical to endogenous BRCA1 in SNU-251 cells; and pcDNA3 (BRCA1 (D1558-1863)), which contains neither BRCT repeat. Each vector was transfected into HeLa The DNA sequence method and a total of 11 PTEN primer sequences were as previously described (Risinger et al., 1996; Steck et al., 1997) . The position of mutation is indicated according to the PTEN genome sequence from gene bank (accession number AF 067844).
Role of BRCA1 in resistance to paclitaxel and ionizing radiation C Zhou et al ) were transiently transfected with 2 mg of BRCA1-expressing vectors using Fugene 6 reagent, in accordance with the manufacturer's protocol. At 48 h after transfection, RNAs were isolated using the Trizol RNA isolation kit and subjected to RT-PCR. For cDNA synthesis, 2 mg of total RNA and random hexamers were added to the reaction mixture, in accordance with the vendor's instructions (Qiagen, Valencia, CA, USA). A 5-ml aliquot of synthesized cDNA was used as a template for amplification of p21 WAF1/CIP1 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as previously described . PCR products were analysed on a 10% polyacrylamide gel and stained with SYBR Green I (FMC BioProducts, Rookland, ME, USA). GAPDH was used as an internal control. Vector, pcDNA3 vector only; wtBRCA1, pcDNA3 (wtBRCA1) vector; BRCA1 (D1815-1863), pcDNA3 (BRCA1 (D1815-1863)) vector; BRCA1 (D1558-1863), pcDNA3 (BRCA1 (D1558-1863)) vector. Vectors were constructed as follows: wild-type BRCA1 cDNA was cut by HindIII and EcoRV from the vector pUHD10.3 (gift from Dr Daniel Haber, Harvard University) and subcloned into the pcDNA3 expression vector to generate vector pcDNA3 (wtBRCA1). The mutant BRCA1 expression vector pcDNA (BRCA1 (D1815-1863) ), which contains a truncated BRCA1 protein without its C-terminal 49 amino acids, was constructed in two steps. First, a DNA fragment containing nucleotides (nt) 4790-5071 of BRCA1 was synthesized by PCR using two primers: forward primer (nt) 4790-4814 5 0 -GATCTAGAGGGAACCCCTTACCTGGAA and reverse primer (nt) 5548-5563 5 0 -CCTCTAGATCAGGCATCTGGCTGCA. An XbaI site (underlined) and a stop codon in the reverse orientation (bold) were included in the reverse primer. Second, the PCR products were purified and cut by XbaI, and the DNA fragment between the XbaI site of the BRCA1 cDNA (at nt 4790) and the XbaI site of the polylinker in pcDNA3 (wtBRCA1) was removed and replaced with the PCR fragment. A mutant BRCA1 expression vector with a deletion of the C-terminal 305 amino acids (BRCA1 (Dl558-1863) ) was constructed by removing the same fragment from the pcDNA3 (wtBRCA1) vector and religating the remaining backbone. , but BRCA1 expression vector without the last 49 amino acids cannot.
It is unclear whether the last 49 amino acids of BRCA1 are sufficient to disrupt BRCA1 function of arresting cells in the G 1 , S, or G 2 /M phase of the cell cycle. As shown in Figure 2e , consistent with SNU-251 and SK-OV3 cells lacking functional p53, neither the SNU-251 nor SK-OV3 cells were arrested in the G 1 phase of the cell cycle after exposure to 10 Gy of g-irradiation. There was also no arrest in the S phase in either cell line after exposure to 10 Gy of g-irradiation. However, both the SNU-251 cells and the SK-OV3 cells were arrested at the G 2 /M phase after exposure to 10 Gy of g-irradiation; the percentages of SNU-251 and SK-OV3 cells in the G 2 /M phase were approximately 51 and 87%, respectively, after 15 h of ionizing radiation, and 55 and 85%, respectively, after 24 h of ionizing radiation ( Figure 2e , Table 2 ). SNU-251 cells exited this G 2 /M cell-cycle arrest after 48 h of ionizing radiation more efficiently than did SK-OV3 cells (24 and 54%, respectively), suggesting that the SNU-251 cells sustained the arrest less efficiently than the SK-OV3 cells did after 48 h.
Loss of the entire second BRCT repeat has been reported to confer sensitivity of HCC1937 breast cancer cells to ionizing radiation ; however, it is unclear whether loss of a portion of the second BRCT repeat causes a similar phenotype. To examine the sensitivity of SNU-251 cells to ionizing radiation, we performed a clonogenic survival assay. Upon treatment with different doses of ionizing radiation, SNU-251 cells showed more sensitivity to the ionizing radiation than did SK-OV3, DOV-13, or MCF-7 cancer cells and NOE cells, all of which contain wild-type BRCA1 (Figure 3a) . This finding implies that partial deletion of the second
SK-OV3

SNU-251
Control 10 Gy Role of BRCA1 in resistance to paclitaxel and ionizing radiation C Zhou et al BRCT domain increased the cells' sensitivity to ionizing radiation, suggesting that both BRCT repeats were necessary to provide resistance to ionizing radiation. This result was confirmed using SNU-251 cells reconstituted with wild-type BRCA1 by transient transfection. When the wild-type BRCA1 was reintroduced into SNU-251 cells, the sensitivity of the cells to various doses of ionizing radiation was decreased compared with the SNU-251 cells without ectopic wild-type BRCA1 (Figure 3b ).
We also investigated whether BRCA1 is involved in resistance of cells to paclitaxel, the most commonly used chemotherapy drugs for patients with ovarian cancer. Upon exposure of SNU-251 cells to different concentrations of paclitaxel for 24 h, cell viability was measured using WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5 tetrazolio]-1,3-benzene disulfonate) reagent (Promega, Madison, WI, USA). The percentage of viable SNU-251 cells after exposure to various concentrations of paclitaxel was lower than the percentage of viable SNU-251 cells reconstituted with wild-type BRCA1 (Figure 3c ). This result implies that mutated BRCA1 sensitized ovarian cancer cells to paclitaxel.
Upon exposure to ionizing radiation, BRCA1 forms discrete subnuclear foci with other DNA-repair proteins, such as RAD51. To examine whether the BRCA1 subnuclear assembly was affected by the loss of the last 49 amino acids, SNU-251 and SK-OV3 cells were exposed to ionizing radiation and then were stained with an anti-BRCA1 (ab1) Relative Survival (% of Untreated Cells) Figure 3 (a) Clonogenic survival assay. SNU-251, SKOV3, MCF-7, DOV-13, and NOE cells were plated and then were either exposed to 1, 2, or 4 Gy of ionizing radiation or mock-exposed (0 Gy). Cells were cultured for 8-10 days, and colonies were stained with crystal violet and counted. Each experiment was repeated three times. Cells were plated so as to produce approximately 30-100 colonies per 60-mm dish at the final count. The number of surviving colonies was normalized to the total number of mockexposed colonies. The survival in the mock-exposed colonies was considered as 100%. Standard error bars are shown on the graph. ) were transiently transfected with 2 mg of pcDNA3 (wtBRCA1) vector using Fugene 6 reagent, in accordance with the manufacturer's protocol. The transfection efficiency was approximately 20%, as measured by b-galactosidase staining. At 24 h after transfection, the cells were diluted and grown in six-well plates. At 8 days after irradiation, the cells were trypsinized and the total cell number was determined by a Coulter counter. The unirradiated cell count from each transfection was set to equal 100%. Relative survival referred to the cell number from a given transfection at a given dose compared with the cell number from an unirradiated plate of the same transfected cells plated on the same day and grown for the same length of time. (~) SNU-251 cells containing pcDNA3 vector; (') SNU-251 cells containing pcDNA3 (wtBRCA1) vector. (c) Viability of SNU-251 cells reconstituted with wild-type BRCA1 after treatment with paclitaxel. At 24 h after the cells were transiently transfected with wild-type BRCA1 vector, the cells were diluted and grown in 96-well plates and then treated with various doses of paclitaxel. Cell viability was measured using a WST-1 kit (Promega, Madison, WI, USA). All experiments were repeated three times, with each sample prepared in triplicate. (~) SNU-251 cells containing pcDNA3 vector; (') SNU-251 cells containing pcDNA3 (wtBRCA1) vector. MCF-7 and DOV-13 cells were cultured in RMPI 1640 medium supplemented with 10% fetal bovine serum and antibiotics at 371C in a 5% CO 2 incubator. Values for untreated cells were defined as 100%
Role of BRCA1 in resistance to paclitaxel and ionizing radiation C Zhou et al SNU-251 cells staining positive for nuclear foci (Figure 4b ). These results imply that the last 49 amino acids of BRCA1 are required for BRCA1 subnuclear assembly after ionizing radiation.
BRCA1-associated breast and ovarian carcinomas have been reported to be associated with high genomic instability, negative estrogen-receptor status, and a high frequency of p53 mutation. We performed a karyotypic analysis of SNU-251 cells, which showed aneuploidy and structural abnormalities, a phenotype commonly associated with ovarian epithelial carcinoma. In four SNU-251 dividing cells analysed, the chromosome number per cell ranged from 69 to 73; each cell had multiple random abnormalities found only in that cell, but there were some abnormalities that were consistent among the cells. Based on a triploid chromosome complement numerical clonal abnormalities included loss of two copies of the X, 2, 14, and 17 chromosomes and loss of one copy of the 10, 12, 15, 16, 18, 21, and 22 chromosomes (Figure 4c ). When telomerase activity in SNU-251 and SK-OV3 cells was examined using the telomerase repeat amplification protocol (TRAP) assay, both cell lines showed high levels of telomerase expression (Figure 4d) , suggesting that the activation of telomerase is an important step for ovarian tumor formation.
Since there is no ovarian cancer cell line in use as a model system to study hereditary human ovarian cancer, we examined the phenotype of SNU-251, a naturally occurring endometrioid ovarian cancer cell line carrying a defective BRCA1 gene. We also examined all nine exons of the PTEN gene in SNU-251 cells because a high incidence of PTEN mutation in endometrioid ovarian cancer was reported previously (Risinger et Role of BRCA1 in resistance to paclitaxel and ionizing radiation C Zhou et al 1996). Our results showed mutations in the introns but not in the exons of the PTEN gene. The SNU-251 cell line has a wild-type PTEN protein, despite the reported high incidence of PTEN mutation in ovarian endometrioid carcinoma (Sato et al., 2000) . We found that in both HeLa cells and SNU-251 cells, loss of the last 49 amino acids of BRCA1 was sufficient to inhibit the transcriptional activation of p21
, which was involved in G 2 /M cell-cycle arrest (el-Deiry et al., 1993; Harper et al., 1993; Dulic et al., 1998) . More investigation is needed to understand the mechanism by which BRCA1 regulates the cell cycles through p21 WAF1/CIP1 . We found that loss of the last 49 amino acids of BRCA1 in SNU-251 cells increased the sensitivity of the cells to ionizing radiation. Such sensitivity was reversible through reintroduction of wild-type BRCA1 expression vector. When cells were treated with different concentrations of paclitaxel, the cell viability of the SNU-251 cells in which the ectopic wild-type BRCA1 had been reintroduced was higher than that of SNU-251 cells Role of BRCA1 in resistance to paclitaxel and ionizing radiation C Zhou et al containing empty vector. Together, all of these results indicate that BRCA1 plays a very important role in the resistance of ovarian cancer cells to ionizing radiation and paclitaxel. It is interesting to note that the SNU-251 cell line also carries a mutant hMLH1 gene (Yuan et al, 1997) ; however, the hMLH1 mutation affects G 2 /M cellcycle arrest after high-dose ionizing irradiation but does affect the survival of the cells (Yan et al., 2001) . The sensitivity of SNU-251 cells to ionizing radiation and paclitaxel was reversed by the reintroduction of BRCA1, suggesting that this sensitivity is BRCA1-specific, not because of a defective hMLH1 gene, although we cannot completely rule out the possibility that an hMLH1 mutation also partially contributes to G 2 /M cell-cycle regulation in SNU-251 cells. An SNU-251 cell line containing an inducible BRCA1 expression vector may help to resolve this issue. We also found that the loss of the last 49 amino acids of BRCA1 in SNU-251 cells prevented BRCA1 subnuclear assembly and impaired DNA repair. As expected, the level of telomerase activity was higher in SNU-251 cells than in NOE cells. Taken together, our results suggest that the SNU-251 cell line could provide a useful model to study the molecular mechanisms involved by BRCA1 in the development of human ovarian cancer and sensitivity to radiation or other chemotherapy drugs used in the treatment of human ovarian cancer carrying the BRCA1 mutation.
